Cargando…

Transcriptional profiles of different states of cancer stem cells in triple-negative breast cancer

Breast cancer stem cells (BCSCs) are thought to be responsible for tumor initiation, metastasis and relapse. Our group and others have described markers useful in isolating BCSCs just as aldehyde dehydrogenase positive (ALDH(+)) or CD24(−)CD44(+). In fact, cells which simultaneously express both set...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Mingshan, Liu, Yang, Deng, Lu, Wang, Dong, He, Xueyan, Zhou, Lei, Wicha, Max S., Bai, Fan, Liu, Suling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824475/ https://www.ncbi.nlm.nih.gov/pubmed/29471829 http://dx.doi.org/10.1186/s12943-018-0809-x

Ejemplares similares

Development of a novel method for rapid cloning of shRNA vectors, which successfully knocked down CD44 in mesenchymal triple-negative breast cancer cells
por: Zhou, Lei, et al.
Publicado: (2018)

NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer
por: Zhou, Lei, et al.
Publicado: (2020)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Mammary stem cells, self-renewal pathways, and carcinogenesis
por: Liu, Suling, et al.
Publicado: (2005)

Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer
por: Liang, Yongxi, et al.
Publicado: (2023)

Epigenetic and transcriptional profiling of triple negative breast cancer
por: Perreault, Andrea A., et al.
Publicado: (2019)

TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer
por: Xu, Jiahui, et al.
Publicado: (2021)

Interfering MSN-NONO complex–activated CREB signaling serves as a therapeutic strategy for triple-negative breast cancer
por: Qin, Yuanyuan, et al.
Publicado: (2020)

Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression
por: Liu, Rong, et al.
Publicado: (2016)

Cancer stem cell heterogeneity in hereditary breast cancer
por: Wicha, Max S
Publicado: (2008)

Single-Cell Proteomic Profiling Identifies Nanoparticle Enhanced Therapy for Triple Negative Breast Cancer Stem Cells
por: Wang, Wenzheng, et al.
Publicado: (2021)

The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling
por: Sharma, Deeksha, et al.
Publicado: (2023)

SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model
por: Kim, Gwangil, et al.
Publicado: (2014)

Syntelin inhibits triple-negative breast cancer cell proliferation and metastasis
por: Mullen, McKay, et al.
Publicado: (2021)

Metabolic plasticity of cancer stem cells
por: Luo, Ming, et al.
Publicado: (2015)

Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers
por: Wang, Lei, et al.
Publicado: (2020)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Modeling of Cancer Stem Cell State Transitions Predicts Therapeutic Response
por: Sehl, Mary E., et al.
Publicado: (2015)

Chemokines and cellular plasticity of ovarian cancer stem cells
por: Zou, Weiping, et al.
Publicado: (2015)

Breast Cancer Stem Cells Transition between Epithelial and Mesenchymal States Reflective of their Normal Counterparts
por: Liu, Suling, et al.
Publicado: (2013)

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
por: Park, So-Yeon, et al.
Publicado: (2019)

Regulation of cancer stem cells in triple negative breast cancer
por: Fultang, Norman, et al.
Publicado: (2021)

Migratory gene expression signature predicts poor patient outcome: Are cancer stem cells to blame?
por: Wicha, Max S
Publicado: (2012)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Construction and Identification of New Molecular Markers of Triple-Negative Breast Cancer Stem Cells
por: Liu, Tingting, et al.
Publicado: (2021)

Mammary stem cell number as a determinate of breast cancer risk
por: Ginestier, Christophe, et al.
Publicado: (2007)

Functional Proteomic Profiling of Triple-Negative Breast Cancer
por: Gromova, Irina, et al.
Publicado: (2021)

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
por: Marqués, Marta, et al.
Publicado: (2022)

Triple-negative breast cancer that progressed as estrogen receptor-positive skin metastases
por: Lee, Sang Min, et al.
Publicado: (2015)

Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer
por: Yang, Chuanwei, et al.
Publicado: (2017)

TP 53 status and estrogen receptor-beta in triple negative breast cancer management in Africa: Time to rethink regime management of triple negative breast cancer and save more lives in Nigeria
por: Nzegwu, Martin Arinzechukwu, et al.
Publicado: (2021)

Roles and expression profiles of long non‐coding RNAs in triple‐negative breast cancers
por: Kong, Xiangyi, et al.
Publicado: (2017)

Cancer Stem Cells and Neovascularization
por: Li, Fengkai, et al.
Publicado: (2021)

Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
por: Li, Liying, et al.
Publicado: (2023)

Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer
por: Liu, Jingxin, et al.
Publicado: (2019)

Interfering with CSE1L/CAS inhibits tumour growth via C3 in triple‐negative breast cancer
por: Ye, Mei, et al.
Publicado: (2022)

THOC2 and THOC5 Regulate Stemness and Radioresistance in Triple‐Negative Breast Cancer
por: Bai, Xupeng, et al.
Publicado: (2021)

Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells
por: Yi, Huimei, et al.
Publicado: (2020)

Classification of triple-negative breast cancers based on Immunogenomic profiling
por: He, Yin, et al.
Publicado: (2018)

Hindering triple negative breast cancer progression by targeting endogenous interleukin‐30 requires IFNγ signaling
por: Sorrentino, Carlo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_81ss421lflkbseo91sdlo7ovus